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Xylitol ingestion causes a small blood glucose rise, and it is
commonly used as an alternative to high energy supplements in
diabetics. In previous studies, a xylitol metabolite, xylulose 5 
phosphate, was shown to activate carbohydrate response element
binding protein, and to promote lipogenic enzyme gene transcrip 
tion in vitro; however, the effects of xylitol in vivo are not under 
stood. Here we investigated the effects of dietary xylitol on lipid
metabolism and visceral fat accumulation in rats fed a high fat
diet. Sprague Dawley rats were fed a high fat diet containing 0 g
(control), 1.0 g/100 kcal (X1) or 2.0 g/100 kcal (X2) of xylitol. After
the 8 week feeding period, visceral fat mass and plasma insulin
and lipid concentrations were significantly lower in xylitol fed
rats than those in high fat diet rats. Gene expression levels of
ChREBP and lipogenic enzymes were higher, whereas the expres 
sion of sterol regulatory element binding protein 1c was lower
and fatty acid oxidation related genes were significantly higher in
the liver of xylitol fed rats as compared with high fat diet rats. In
conclusion, intake of xylitol may be beneficial in preventing the
development of obesity and metabolic abnormalities in rats with
diet induced obesity.
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Introduction Visceral fat obesity has become a severe problem in the world
and is a major risk factor for many diseases, such as
metabolic syndrome, atherosclerosis, cardiovascular disease,
stroke, and even cancer.(1–3) Recently, it has been established that
obesity is caused by various environmental factors, including
dietary energy content and nutrient composition.(4,5) A high-fat
diet induces obesity, hyperglycemia, dyslipidemia and hyper-
insulinemia, leading to insulin resistance and type 2 diabetes.(6,7) In
rodents, such overnutrition as high-fat feeding activates sterol
regulatory-element binding protein 1c (SREBP-1c) in the liver,
and the increased accumulation of fat promotes metabolic
syndrome.(8,9) In addition, SREBP-1c plays a key role in the
mechanism of high-fat-induced obesity and insulin resistance in
the liver.(10) A high-fat diet leads to the increased expression of fatty
acid oxidation-related genes including peroxisome proliferators-
activated receptor (PPAR) α in the liver to allow adaptation to the
high intake of fat.(8) However, an impaired ability to increase fat
oxidation in response to a high-fat diet leads to the development of
obesity and insulin resistance.(11)
Xylitol is a five-carbon sugar alcohol with an energy value of
3 kcal/g. Significant quantities of xylitol have been detected in a
wide variety of plants, including fruits and vegetables such as
plums, strawberries, raspberries, and cauliflower.(12) It is used
widely as a low-calorie sweetener in medications, dental care
products, chewing gums, and candies. Xylitol is absorbed from
the small intestine by passive diffusion and is mostly metabolized
in the liver.(13) The ingestion of xylitol causes a smaller rise in
plasma glucose and insulin concentrations than does the ingestion
of glucose in healthy men and diabetics.(14,15) Hence, it has been
used in patients with diabetes mellitus as an energy source in place
of other carbohydrates. In the liver, xylitol is phosphorylated and
metabolized to xylulose 5-phosphate (Xu5P), an intermediate of
the nonoxidative branch of the pentose phosphate pathway.(16–18)
The xylitol metabolite Xu5P specifically activates both nuclear
transport and the DNA-binding activities of carbohydrate response
element binding protein (ChREBP) through the activation of
protein phosphatase 2A (PP2A) in vitro.(19,20) ChREBP is a tran-
scription factor that activates lipogenic enzyme genes, such as
acetyl coenzyme A carboxylase (ACC) and fatty acid synthase
(FAS), and that stimulates lipogenesis in the liver.(21,22) Enhanced
hepatic lipogenesis result in steatosis and obesity.(23,24) If xylitol
stimulates lipogenesis, it might induce steatosis and obesity,
leading to metabolic syndrome. In addition, the long-term effects
of xylitol intake on lipid metabolism are not fully understood.
In the present study, we investigated the effects of dietary
xylitol on visceral fat accumulation and lipid metabolism in rats
fed a high-fat diet.
Materials and Methods
Animals. Sprague-Dawley (SD) rats were purchased from the
Japan SLC (Hamamatsu, Japan) and used in all experiments. The
rats were individually caged in the facility under a 12-h light/dark
cycle and constant temperature (23 ± 2°C). Prior to the initiation
of our study, the rats were fed a standard rodent diet (MF; Oriental
Yeast, Tokyo, Japan) and water ad libitum. This study was ap-
proved by the Tokushima University Animal Use Committee, and
the rats were maintained according to guidelines of Tokushima
University for care of laboratory animals.
Diet and experimental design of long term xylitol feeding
test. Eighteen male, 9-week-old SD rats (weight 290–310 g)
were used in a long-term xylitol feeding test. After acclimation for
2 weeks, the rats were divided into 3 groups (6 rats per group) and
subjected to the following studies. The rats were fed one of three
high-fat-based diets containing different amounts of xylitol: 0 g
(HFD, control), 1.0 g/100 kcal (X1) or 2.0 g/100 kcal (X2). The
exact composition of each diet is shown in Table 1. Xylitol was
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substituted with starch, because sucrose contents have greater
effects on serum lipid levels, postprandial glucose level, and
body fat mass than starch.(26–28) To eliminate impact of differences
in energy states on body fat mass, isocaloric pair-feeding was
performed through the feeding period. Food intake was monitored
daily, and body weight was recorded weekly throughout the
feeding period. After 8 week, blood samples were collected
from the tail vein for the determination of plasma glucose and
insulin levels after 12 h of food deprivation. The rats were then
anesthetized with diethylether and blood was withdrawn from the
jugular vein for the determination of all other measurements. After
the rats were killed by exsanguination, organs including the liver,
visceral fat and soleus muscle were collected, weighted and stored
at −80°C until analysis.
Plasma glucose, insulin and lipids measurements.
Plasma glucose levels were measured by the glucose dehydro-
genase method using an Accu-Chek blood glucose meter (Roche
Diagnostics, Mainz-Hechtsheim, Germany). Plasma insulin
levels were measured by ELISA (Morinaga, Yokohama, Japan).
Plasma triglyceride, total cholesterol and non-esterified fatty acids
(NEFA) concentrations were measured by enzymatic methods
using Triglyceride E, Cholesterol E and NEFA C-tests (Wako,
Osaka, Japan), respectively.
Hepatic lipids concentration. Hepatic lipids were extracted
from 1.0 g of liver with chloroform/methanol (2:1 v/v), according
to the method of Folch et al.(29) Triglyceride and cholesterol
concentrations were determined in the extracted samples by
commercial kits (Triglyceride E and Cholesterol E-tests).
RNA preparation and quantitative RT PCR. Total RNA was
isolated from frozen liver and mesenteric adipose tissue samples
with TRIzol Regent (Invitrogen, Carlsbad, CA) and RNeasy kit
(QIAGEN, Tokyo, Japan), respectively. First-standard cDNAs
were synthesized with M-MLV reverse transcriptase (Invitrogen)
and oligo-dT primer. We performed real-time PCR by using the
primers described in Table 2, and SYBR green dye (SYBR Premix
Ex Taq; TAKARA BIO, Shiga, Japan) in a LightCycler real-time
PCR system (Roche Diagnostics), according to the manufacturer’s
instructions. The relative amounts of mRNA were calculated with
β-actin mRNA as the invariant control. The ratio for the data from
the HFD group was set arbitrarily at 1.
Primary culture of hepatocytes. Hepatocytes were isolated
from male SD rats aged 6–10 weeks using the collagenase perfu-
sion method.(30) The cells were cultured in glucose-free Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 1 nmol/l
of insulin (Sigma, St. Louis, MO), 1 nmol/l of dexamethasone
(Sigma), 10% (v/v) fetal bovine serum (Invitrogen), and 1% (v/v)
penicillin-streptomycin (Sigma). After 6 h of attachment, the
medium was removed and changed to fresh medium. After an
overnight culture, cells were stimulated with 5 mmol/l xylitol
for 16 h, after which total RNA was extracted (n = 3 in each
experiment) and cDNA synthesis and real-time PCR analysis was
performed.
Effects of xylitol on postprandial glucose and insulin
levels in rats. Male SD rats aged 10–13 weeks were used in an
oral sucrose tolerance test. Before 4 days of the oral study, rats
underwent a catheterization to insert catheter into the left femoral
vein as described previously.(31) After an overnight fast (18–20 h),
sucrose (1 g/kg body weight), either alone or with xylitol (0.25 g/kg
body weight), was orally administered to rats. Mannitol, a type of
sugar alcohol, was used as a reference against xylitol. Blood
samples were taken from the femoral vein of unanesthetized rats
at 0, 30, 60 and 120 min after administration.
Statistical analysis. Values are expressed as means ± SEM.
Significance of the differences was determined by analysis of
variance (ANOVA) or the Kruskal-Wallis test, followed by the
post-hoc test. Differences with a value of p<0.05 were considered
significant. Statistical tests were performed with Excel-Toukei
2006 (SSRI, Tokyo, Japan).
Results
Xylitol supplimentation suppresses visceral fat accumula 
tion induced by HFD. During the 8-week feeding period, the
energy intake was similar in all groups (Table 3). Diarrhea was
not found in any rats throughout the study. After the experimental
period, body weight did not differ among the groups; however, the
accumulation of visceral fat was significantly smaller in the
xylitol-fed (X1 and X2) groups than in the control (HFD) group
(p<0.05; Table 3). In particular, the relative weight of mesenteric
fat was significantly lower in the xylitol-fed (X2) group than in the
HFD group by 23.2% (p<0.05; Table 3). In addition, the relative
weight of epididymal fat was significantly lower in the xylitol-fed
(X1 and X2) groups than in the HFD group by 15.5% and 17.0%,
respectively (p<0.05; Table 3). The relative weights of soleus
muscle and liver, and the hepatic triglyceride and cholesterol
concentrations were not affected by dietary interventions (Table 3).
Xylitol supplementation suppresses the increrased insu 
linemia and lipidemia induced by HFD. The plasma glucose
and non-esterified fatty acid (NEFA) concentrations did not differ
among the three groups (Fig. 1). The plasma insulin and triglyceride
concentrations were significantly lower in the xylitol-fed (X2)
group than in the HFD group by 29.3% and 54.5%, respectively
(p<0.05; Fig. 1). The plasma total cholesterol concentrations in
the xylitol-fed (X1 and X2) groups were significantly reduced as
compared with the HFD group (p<0.05; Fig. 1).
Adipose gene expression in xylitol long term feeding
test. As shown in Table 3, the visceral fat mass, especially
mesenteric and epididymal fat mass, was significantly lower in the
xylitol-fed (X1 and X2) groups than in the HFD group. Therefore,
we examined the expression of lipid metabolism-related genes in
the mesenteric adipose tissue by real-time RT-PCR. The mRNA
levels of PPARγ, a key regulator of adipocyte differentiation, and
the insulin-sensitizing hormone adiponectin were significantly up-
regulated in the xylitol-fed (X2) group as compared with the HFD
group (p<0.05; Fig. 2). Moreover, the mRNA levels of hormone
sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), the
lipolytic enzymes in adipocytes, were significantly elevated in the
xylitol-fed (X2) group as compared with the HFD group (p<0.05;
Fig. 2).
Hepatic gene expression in xylitol long term feeding
test. To investigate the molecular mechanisms underlying the
Table 1. Composition of experimental diets
HFD, high fat diet; X1, high fat diet containing xylitol at 1.0 g/100 kcal;
X2, high fat diet containing xylitol at 2.0 g/100 kcal. † AIN 93M(25).
Composition
Diet
HFD X1 X2
g/kg diet
Milk casein 222.5 222.5 222.5
L Cystine 2.5 2.5 2.5
Lard 150.0 150.0 150.0
Soybean oil 50.0 50.0 50.0
Cornstarch 312.3 267.3 222.3
α Cornstarch 50.0 50.0 50.0
Sucrose 100.0 100.0 100.0
Xylitol 0.0 45.0 90.0
Vitamin mixture† 12.5 12.5 12.5
Mineral mixture† 50.0 50.0 50.0
Fiber (cellulose) 45.0 45.0 45.0
Choline bitartrate 3.2 3.2 3.2
tert butylhydroquinone 0.01 0.01 0.01
Vitamin E acetate 2.0 2.0 2.0 J. Clin. Biochem. Nutr. | July 2011 | vol. 49 | no. 1 | 3
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effects of xylitol on hepatic lipid metabolism in vivo, we examined
the expression levels of lipid metabolism-related genes in the liver
by real-time RT-PCR. The mRNA levels of ChREBP, and the
lipogenic enzymes ACC and FAS were higher in the xylitol-fed
(X1 and X2) groups than in the HFD group (p<0.05; Fig. 3A). On
the other hand, the mRNA level of another lipogenic transcription
factor SREBP-1c, which regulated principally by insulin,(32) was
significantly lower in the xylitol-fed (X2) group than in the HFD
group (p<0.05; Fig. 3A). The mRNA levels of the transcription
factors PPARα and PPARγ coactivator 1α (PGC-1α) which
regulate fatty acid oxidation were significantly higher in the
xylitol-fed (X2) group than in the HFD group (p<0.05; Fig. 3B).
The mRNA levels of acyl-coenzyme A oxidase (ACO) and un-
coupling protein 2 (UCP2), downstream target genes of PPARα
were significantly higher in the xylitol-fed (X1 and X2) groups
than in the HFD group (p<0.05; Fig. 3B). Additionally, the expres-
Table 2. Sequence of oligonucleotide primers for quantitative RT PCR analysis
F, forward; R, reverse; PPAR, peroxisome proliferator activated receptor; HSL, hormone sensitive lipase;
ATGL, adipose trigyceride lipase; SREBP 1c, sterol regulatory element binding protein 1c; ChREBP,
carbohydrate response element binding protein; ACC, acetyl coenzyme A carboxylase; FAS, fatty acid
synthase; ACO, acyl coenzyme A oxidase; UCP2, uncoupling protein 2; PGC 1α, peroxisome proliferator 
activated receptor gamma coactivator 1α; CYP7A1, cholesterol 7α hydroxylase; ABCG5, ATP binding
cassette subfamily G member 5.
Gene name Size (bp) Accession No. Primer sequence
PPARγ 147 AF156665 F: 5' GGAAACTTGTGCAAGGTTGGA 3'
R: 5' CAGGCTCTACTTTGATCGCA 3'
adiponectin 140 NM_144744 F: 5' GGAAACTTGTGCAAGGTTGGA 3'
R: 5' GGTCACCCTTAGGACCAAGA 3'
HSL 229 X51415 F: 5' AGAGCCATCAGACAGCCCCGAGAT 3'
R: 5' TGACGAGTAGAGGGGCATGTGGAG 3'
ATGL 148 NM_001108509 F: 5' GAGATGTGCAAACAGGGCTA 3'
R: 5' CAGTCCTCTCCTCAGTCACG 3'
SREBP 1c 190 AF286470 F: 5' GGAGCCATGGATTGCACATTT 3'
R: 5' TCCTTCCGAAGGTCTCTCCTC 3'
ChREBP 113 AB074517 F: 5' CAGCTTCTCGACTTGGACTG 3'
R: 5' TTGCCAACATAAGCGTCTTC 3'
ACC 233 J03803 F: 5' CCAGTCTACATCCGCTTGGCTGAG 3'
R: 5' AGTCGCCAGTAGAAGAAGGTGCGG 3'
FAS 104 M76767 F: 5' TGGGCCCATCTTCTTAGCC 3'
R: 5' GGAACAGCGCAGTACCGTAGA 3'
PPARα 112 M88529 F: 5' TGTATGAAGCCATCTTCACG 3'
R: 5' GGCATTGAACTTCATAGCGA 3'
ACO 114 J02752 F: 5' ATGGCAGTCCGGAGAATACCC 3'
R: 5' CCTCATAACGCTGGCTTCGAGT 3'
UCP2 107 NM_019354 F: 5' TCTCCCAATGTTGCCCGAAA 3'
R: 5' GGGAGGTCGTCTGTCATGAG 3'
PGC 1α 109 AY237127 F: 5' TGTTCGATGTGTCGCCTTGT 3'
R: 5' GAACGAGAGCGCATCCTTTG 3'
CYP7A1 127 NM_012942 F: 5' CACCTTTGACGACATGGAGAAG 3'
R: 5' TGCTTTCATTGCTTCAGGACTC 3'
ABCG5 111 NM_053754 F: 5' TGTGTTACTGGACTCTGGGC 3'
R: 5' CAAGCAGCACAAGTGTCAGA 3'
β actin 171 NM_031144 F: 5' GTCCCAGTATGCCTCTGGTCGTAC 3'
R: 5' CCACGCTCGGTCAGGATCTTCATG 3'
Table 3. Energy intake, body and organ weights, and hepatic lipid concentrations in rats fed three
different diets for 8 week
Values are mean ± SEM, n =6 .  * p<0.05 vs HFD group.
HFD X1 X2
Energy intake, kcal/d 95.5 ± 1.1 94.1 ± 1.2 93.5 ± 1.2
Body weight, g 543.2 ± 10.2 525.1 ± 9.6 540.4 ± 9.9
Visceral fat, g/kg body weight 96.7 ± 3.8 84.2 ± 5.3* 81.7 ± 4.2*
Mesenteric fat 27.5 ± 1.3 25.4 ± 1.3 21.1 ± 1.0*
Epididymal fat 30.2 ± 2.1 25.6 ± 1.5* 25.1 ± 1.9*
Retroperitoneal fat 39.0 ± 1.7 33.2 ± 3.9 35.5 ± 2.1
Soleus muscle, g/kg body weight 0.64 ± 0.02 0.68 ± 0.02 0.66 ± 0.04
Liver, g/kg body weight 29.7 ± 1.1 29.6 ± 1.1 28.4 ± 1.2
Liver triglyceride, µmol/γ tissue 21.1 ± 4.3 27.3 ± 5.4 22.6 ± 5.6
Liver cholesterol, µmol/γ tissue 3.7 ± 0.6 4.5 ± 0.6 3.9 ± 0.7doi: 10.3164/jcbn.10 111
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sion levels of genes involved in bile acid synthesis and cholesterol
metabolism such as cholesterol 7α hydroxylase (CYP7A1) and
ATP-binding cassette, subfamily G, member 5 (ABCG5) increased
in the xylitol-fed (X2) group compared with HFD group (p<0.05;
Fig. 3C).
Effect of xylitol on gene expression in rat primary hepato 
cytes. Xylitol is metabolized predominantly in the liver,(13) so we
next investigated the direct effect of xylitol on lipid metabolism-
related gene expression using rat primary hepatocytes. Xylitol
induced lipogenic gene expressions including ChREBP and FAS
(p<0.05; Fig. 4A), as well as previously reported.(19,33) Moreover,
xylitol also induced fatty acid oxidation-related gene expressions
including PPARα and ACO as observed in long-term feeding test
(p = 0.057 and p<0.05; Fig. 4B). However, the direct effect of
xylitol on PPARα and ACO seems to be not so potent. In addition,
xylitol stimulation did not change the expression level of SREBP-
1c differently from the result in vivo (Fig. 4A). These results
indicated that xylitol could also have the indirect effect on hepatic
gene expression.
Xylitol suppresses postprandial rises in blood glucose and
insulin in rats. In the long-term xylitol feeding test, fasting
plasma insulin level was reduced in the xylitol-fed groups than in
the HFD group (Fig. 1). One potential factor that regulates lipo-
genic gene expression is insulin. Thus, we investigated whether
xylitol suppress the postprandial rises in blood glucose and insulin
by performing the oral co-administration with sucrose to rats as
described previously.(34,35) The plasma glucose levels were signifi-
cantly reduced by the coadministration of xylitol at 30 min after
the sucrose administration (p<0.05; Fig. 5A). In addition, the co-
administration of xylitol tended to decrease the plasma insulin
levels (Fig. 5B). There were no significant differences in the
plasma glucose and insulin levels between the sucrose alone and
the coadministration of mannitol (Fig. 5 A and B). These data
showed that xylitol could suppress postprandial rise in glucose and
insulin levels.
Discussion
In the present study, we demonstrated that long-term intake of
xylitol suppressed the accumulation of visceral fat and the increase
in plasma insulin and lipids concentrations in rats fed a high-fat
diet. Intake of xylitol stimulated the expression of fatty acid
oxidation genes in the liver, and lipid degradation and adiponectin
genes in the adipose tissue. Furthermore, in oral sucrose tolerance
test, we found for the first time that xylitol ingestion lowered
postprandial hyperglycemia. The dose of xylitol in this study is the
non-effective dose in causing diarrhea, and within the limits of
orally administered physiological amounts (1–4 g/kg body weight
daily) of xylitol on human and rats identified previously.(36,37)
The adipose tissue of xylitol-fed rats showed significantly
higher levels of mRNAs encoding PPARγ, adiponectin, HSL and
ATGL. These data indicates a miniaturization of adipocytes and
lipolysis were caused in the adipose tissue, that they could con-
tribute to lowering fat mass in xylitol-fed rats. PPARγ is mainly
expressed in adipose tissue, which triggers adipocyte differentia-
tion,(38) and it up-regulates the expression level of adiponectin in
small adipocytes.(39) Adiponectin is an important modulator of
insulin sensitivity and activates PPARα, thereby stimulating fatty
acid oxidation in the liver.(40) In addition, PPARγ agonists can
stimulate lipolysis by increasing the expression levels of lipolysis-
related enzymes, including HSL and ATGL in adipose tissue.(41)
Therefore, these observations suggest that the elevation in PPARγ
expression in the adipose tissue of rats fed a high-fat diet with
xylitol might contribute to the suppression of visceral fat accumu-
lation and increased level of adiponectin mRNA that occurs
concomitantly with the provision of fatty acid as an energy source
to the liver. At present, however, it is uncertain how dietary xylitol
promotes the expression of PPARγ in adipose tissue. Because
xylitol is mainly metabolized in the liver(16–18) and little is taken up
into adipose tissue,(42,43) the effects of xylitol on adipose tissue may
be not a direct effect. Additional studies are needed to investigate
the underlying mechanism.
In the liver, two main transcription factors regulate the gene
Fig. 1. Plasma glucose, insulin, and lipids levels in rats fed three different diets for 8 week. Values are mean ± SEM (n = 6 for each group). *p<0.05
vs HFD group. TG, triglyceride; T Chol, total cholesterol; NEFA, non esterified fatty acid.
Fig. 2. Adipose gene expression in rats fed three different diets for 8 week. mRNA levels of genes in the mesenteric fat tissues were determined by
quantitative RT PCR analysis. Values are mean ± SEM (n = 5 for each group). *p<0.05 vs HFD group. The ratio for the data from the HFD group was
set arbitrarily at 1. PPARγ, peroxisome proliferator activated receptor γ; HSL, hormone sensitive lipase; ATGL, adipose triglyceride lipase. J. Clin. Biochem. Nutr. | July 2011 | vol. 49 | no. 1 | 5
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expression of lipogenic enzymes: one is SREBP-1c, whose
expression can be up-regulated by insulin;(32) the other is ChREBP,
which can be activated by the xylitol metabolite Xu5P through
the activation of PP2A, independently of insulin.(21,22) Although it
has been reported that SREBP-1c and ChREBP synergistically
regulate lipogenesis,(44) the liver of xylitol-fed rats showed the
increase in the expression of ChREBP and the reduction of
SREBP-1c in the long-term xylitol feeding test, and caused the
suppression of visceral fat accumulation, resulting from not
trending toward an increase in lipid synthesis. When we tried to
confirm the direct effect of xylitol on above-mentioned genes
expression related to hepatic lipid metabolism by using rat primary
hepatocytes, xylitol induced the gene expression of ChREBP,
but did not affect SREBP-1c. In oral sucrose tolerance test, xylitol
supplementation exhibited a suppression of postprandial hyper-
glycemia. Therefore, the suppression of plasma insulin levels in
xylitol-fed rats of the long-term test could be attributed to the
suppression of postprandial hyperglycemia. The smaller demand
for insulin secretion in xylitol-fed rats can contribute to lower the
level of plasma insulin and the hepatic lipid metabolism-related
gene expression. Because SREBP-1c is regulated mainly by
insulin, a low level of SREBP-1c mRNA expression in vivo
study might be caused by the suppression of insulin secretion in
xylitol-fed rats.
In the current in vivo study, the liver of xylitol-fed rats showed
a significant increase in mRNAs levels of the genes encoding
PPARα, PGC-1α, ACO and UCP2, which are related to fatty acid
Fig. 3. Hepatic gene expression in rats fed three different diets for 8 week. mRNA levels of genes related to (A) lipogenesis, (B) fatty acid oxidation,
and (C) cholesterol metabolism in the liver were determined by quantitative RT PCR analysis. Values are mean ± SEM (n = 6 for each group). *p<0.05
vs HFD group. The ratio for the data from the HFD group was set arbitrarily at 1. SREBP 1c, sterol regulatory element binding protein 1c; ChREBP,
carbohydrate response element binding protein; ACC, acetyl coenzyme A carboxylase; FAS, fatty acid synthase; PPARα, peroxisome proliferator 
activated receptor α; ACO, acyl coenzyme A oxidase; UCP2, uncoupling protein 2; PGC 1α, peroxisome proliferator activated receptor gamma
coactivator 1α; CYP7A1, cholesterol 7α hydroxylase; ABCG5, ATP binding cassette subfamily G member 5.
Fig. 4. Effects of xylitol on gene expression in rat primary hepatocytes.
Xylitol stimulation was performed in rat primary hepatocytes, and
mRNA levels of genes related to (A) lipogenesis and (B) fatty acid
oxidation were determined by quantitative RT PCR analysis. Values are
mean ± SEM, n = 3. *p<0.05 vs control (  xylitol) group.doi: 10.3164/jcbn.10 111
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oxidation.(45,46) Activation of PPARα not only suppresses adipo-
cyte hypertrophy in adipose tissue but also stimulates fatty acid
oxidation in the liver.(47) In addition, the rate of fatty acid oxidation
in the liver is a major determinant of plasma triglyceride levels.(48)
The increased fatty acid oxidation-related gene expression may
also contribute to the suppression of visceral fat accumulation in
xylitol-fed rats. However, it is likely that the direct effect of xylitol
on the induction of PPARα and oxidation-related enzyme is not
much powerful as shown Fig. 4B. The other candidate for the
regulator of fatty acid oxidation can be suspected insulin. The
attenuation of hyperinsulinemia enhances fat oxidation rates, and
assist in preventing obesity and insulin resistance.(49,50) And,
insulin negative-regulator of fatty acid oxidation-related gene
expression including PPARα.(51,52) Therefore, it is possible that
hepatic oxidation-related gene expression in xylitol-fed rats could
be affected by insulin. Taken together, hepatic lipid metabolism
in xylitol-fed rats might be affected predominantly by the suppres-
sion of insulin, and contribute to lower visceral fat accumulation.
Because xylitol intake attenuated the increase in plasma insulin
induced by HFD and postprandial hyperglycemia, it may be
possible that intake of xylitol prevents the onset or progression
of type 2 diabetes. However, further studies using model animals
of diabetes are needed.
Conclusion
To date, xylitol is used widely in foods and medications, but its
metabolite has been reported to activate ChREBP, up-regulating
the gene transcription of lipogenic enzymes in vitro. This dis-
crepancy suggests caution in the use of xylitol for the patients
with obesity, type 2 diabetes, and other metabolic disorders. Our
study has demonstrated that the intake of xylitol in vivo did not
cause problems with lipogenesis, because of the suppression of
high-fat induced-visceral fat accumulation. In addition, xylitol
may have some beneficial effects such as lower postprandial
hyperglycemia. These preferable effects suggest that xylitol intake
may be useful to control or prevent humans from obesity, diabetes,
and other metabolic disorders.
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SREBP-1c sterol regulatory-element binding protein 1c
UCP2 uncoupling protein 2
X1 high-fat diet containing xylitol at 1.0 g/100 kcal
X2 high-fat diet containing xylitol at 2.0 g/100 kcal
References
1 Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature
2009; 444: 881–887.
2 Nammi S, Koka S, Chinnala KM, Boini KM. Obesity: an overview on its
current perspectives and treatment options. Nutr J 2003; 3: 3.
3 Akagiri S, Naito Y, Ichikawa H, and et al. A mouse model of metabolic
syndrome; Increase in visceral adipose tissue precedes the development of
fatty liver and insulin resistance in high-fat-diet fed-male KK/Ta mice. J Clin
Biochem Nutr 2008; 42: 150–157.
4 Bray GA, Lovejoy JC, Smith SR, and et al. The influence of different fats
and fatty acids on obesity, insulin resistance and inflammation. J Nutr 2002;
132: 2488–2491.
5 Watanabe K, Arozal W, Tanaka H, and et al. Beneficial effect of food sub-
Fig. 5. Effect of oral sucrose administration with or without xylitol on plasma glucose and insulin levels. After fasting for 18–20 h, the rats were
orally administrated sucrose (1 g/kg body weight) either alone or with xylitol or mannitol (0.25 g/kg body weight). Blood samples were taken at 0,
30, 60 and 120 min after administration. (A, B) Time dependent curve for plasma levels of (A) glucose and (B) insulin. Values are mean ± SEM, n =4 –
7. *p<0.05 vs S group. S, sucrose (1 g/kg body weight); SX, sucrose (1 g/kg body weight) with xylitol (0.25 g/kg body weight); SM, sucrose (1 g/kg
body weight) with mannitol (0.25 g/kg body weight). J. Clin. Biochem. Nutr. | July 2011 | vol. 49 | no. 1 | 7
©2011 JCBN
K. Amo et al.
stitute containing L-arginine, omega-3 poly unsaturated fatty acid, and ribo-
nucleic acid in preventing or improving metabolic syndrome: a study in 15
overweight patients and a study of fatty acid metabolism in animals. J Clin
Biochem Nutr 2009; 44: 266–174.
6 Martins IJ, Redgrave TG. Obesity and post-prandial lipid metabolism. Feast
or famine? J Nutr Biochem 2004; 15: 130–141.
7 Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-
induced type II diabetes in C57BL/6J mice. Diabetes 1988; 37: 1163–1167.
8 Kennedy AR, Pissios P, Out H, and et al. A high-fat, ketogenic diet induces a
unique metabolic state in mice. Am J Physiol Endocrinol Metab 2007; 292:
E1724–E1739.
9 Murase T, Mizuno T, Omachi T, and et al. Dietary diacylglycerol suppresses
high fat and high sucrose diet-induced body fat accumulation in C57BL/6J
mice. J Lipid Res 2001; 42: 372–378.
10 Ide T, Shimano H, Yahagi N, and et al. SREBPs suppress IRS-2-mediated
insulin signalling in the liver. Nat Cell Biol 2004; 6: 351–357.
11 Heilbronn LK, Gregersen S, Shirkhedkar D, Hu D, Campbell LV. Impaired
fat oxidation after a single high-fat meal in insulin-sensitive nondiabetic
individuals with a family history of type 2 diabetes. Diabetes 2007; 56: 2046–
2053.
12 Georgieff M, Moldawer LL, Bistrian BR, Blackburn GL. Xylitol, an energy
source for intravenous nutrition after trauma. JPEN J Parenter Enteral Nutr
1985; 9: 199–209.
13 Dills WL Jr. Sugar alcohols as bulk sweeteners. Annu Rev Nutr 1989; 9: 161–
186.
14 Goto Y, Anzai M, Chiba M, Ohneda A, Kawashima S. Clinical effects of
xylitol on carbohydrate and lipid metabolism in diabetes. Lancet 1965; 2:
918–921.
15 Natah SS, Hussien KR, Tuominen JA, Koivisto VA. Metabolic response to
lactitol and xylitol in healthy men. Am J Clin Nutr 1977; 65: 947–950.
16 Mäkinen KK. Biochemical principles of the use of xylitol in medicine and
nutrition with special consideration of dental aspects. Experientia Suppl 1978;
30: 1–160.
17 Mäkinen KK. Can the pentitol-hexitol theory explain the clinical observa-
tions made with xylitol? Med Hypotheses 2000; 54: 603–613.
18 Woods HF, Krebs HA. Xylitol metabolism in the isolated perfused rat liver.
Biochem J 1973; 134: 437–443.
19 Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K. Xylulose 5-phosphate
mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated
protein phosphatase in rat liver. Proc Natl Acad Sci USA 2003; 100: 5107–
5112.
20 Kawaguchi T, Takenoshita M, Kabashima T, Uyeda K. Glucose and cAMP
regulate the L-type pyruvate kinase gene by phosphorylation/dephosphoryla-
tion of the carbohydrate response element binding protein. Pro Natl Acad Sci
USA 2001; 98: 13710–13715.
21 Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K. Deficiency of carbo-
hydrate response element-binding protein (ChREBP) reduces lipogenesis as
well as glycolysis. Proc Natl Acad Sci USA 2004; 101: 7281–7286.
22 Ishii S, Iizuka K, Miller BC, Uyeda K. Carbohydrate response element
binding protein directly promotes lipogenic enzyme gene transcription. Proc
Natl Acad Sci USA 2004; 101: 15597–15602.
23 Kusunoki J, Kanatani A, Moller DE. Modulation of fatty acid metabolism as
a potential approach to the treatment of obesity and the metabolic syndrome.
Endocrine 2006; 29: 91–100.
24 Postic C, Girard J. The role of the lipogenic pathway in the development of
hepatic steatosis. Diabetes Metab 2008; 34: 643–648.
25 Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory
rodents: final report of the American Institute of Nutrition ad hoc writing
committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;
123: 1939–1951.
26 Daly M. Sugars, insulin sensitivity, and the postprandial state. Am J Clin Nutr
2003; 78: 865S–872S.
27 Fried SK, Rao SP. Sugars, hypertriglyceridemia, and cardiovascular disease.
Am J Clin Nutr 2003; 78: 873S–880S.
28 Vermunt SH, Pasman WJ, Schaafsma G, Kardinaal AF. Effects of sugar
intake on body weight: a review. Obes Rev 2003; 4: 91–99.
29 Folch J, Less M, Sloane Stanley GH. A simple method for the isolation and
purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497–
509.
30 Uebanso T, Taketani Y, Fukaya M, and et al. Hypocaloric high-protein diet
improves fatty liver and hypertriglyceridemia in sucrose-fed obese rats via
two pathways. Am J Physiol Endocrinol Metab 2009; 297: E67–E84.
31 Fukaya M, Mizuno A, Arai H, and et al. Mechanism of rapid-phase insulin
response to elevation of portal glucose concentration. Am J Physiol Endocrinol
Metab 2007; 293: E515–E522.
32 Foretz M, Guichard C, Ferré P, Foufelle F. Sterol regulatory element binding
protein-1c is a major mediator of insulin action on the hepatic expression of
glucokinase and lipogenesis-related genes. Proc Natl Acad Sci USA 1999; 96:
12737–12742.
33 Mourrieras F, Foufelle F, Foretz M, Morin J, Bouche S, Ferre P. Induction
of fatty acid synthase and S14 gene expression by glucose, xylitol and
dihydroxyacetone in cultured rat hepatocytes is closely correlated with glucose
6-phosphate concentrations. Biochem J 1997; 326: 345–349.
34 Uebanso T, Arai H, Taketani Y, and et al. Extracts of Momordica charantia
suppress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol (Tokyo)
2007; 53: 482–488.
35 Matsuo T, Izumori T. d-Psicose inhibits intestinal alpha-glucosidase and
suppresses the glycemic response after ingestion of carbohydrates in rats. J
Clin Biochem Nutr 2009; 45: 202–206.
36 Makinen KK, Ylikahri R, Makinen PL, Soderling E, Hamalainen M. Turku
sugar studies XXIII. Comparison of metabolic tolerance in human volunteers
to high oral doses of xylitol and sucrose after long-term regular consumption
of xylitol. Int J Vitam Nutr Res Suppl 1982; 22: 29–49.
37 Hamalainen M, Makinen KK. Effect of peroral xylitol on the concentration
levels of lipids and electrolytes in rat tessues. Nutr Res 1983; 3: 497–510.
38 Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear
control of metabolism. Endocr Rev 1999; 20: 649–688.
39 Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, Smith U. Improved
insulin sensitivity and adipose tissue dysregulation after short-term treatment
with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia
2005; 48: 96–104.
40 Yamauchi T, Kamon J, Waki H, and et al. The fat-derived hormone
adiponectin reverses insulin resistance associated with both lipoatrophy and
obesity. Nat Med 2001; 7: 941–946.
41 Festuccia WT, Laplante M, Berthiaume M, Gélinas Y, Deshaies Y.
PPARgamma agonism increases rat adipose tissue lipolysis, expression of
glyceride lipases, and the response of lipolysis to hormonal control.
Diabetologia 2006; 49: 2427–2436.
42 Quadflieg KH, Brand K. Comparison of xylitol and glucose metabolism in
nonhepatic rat tissues. Z Ernahrungswiss 1976; 15: 345–354.
43 Wang MC, Meng HC. Xylitol metabolism in extrahepatic tissues. Z
Ernahrungswiss Suppl 1971; 11: 8–16.
44 Dentin R, Girard J, Postic C. Carbohydrate responsive element binding
protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-
1c): two key regulators of glucose metabolism and lipid synthesis in liver.
Biochimie 2005; 87: 81–86.
45 Mandard S, Müller M, Kersten S. Peroxisome proliferator-activated receptor
alpha target genes. Cell Mol Life Sci 2004; 61: 393–416.
46 Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with
peroxisome proliferator-activated receptor alpha in transcriptional control of
nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell
Biol 2000; 20: 1868–1876.
47 Tsuchida A, Yamauchi T, Takekawa S, and et al. Peroxisome proliferator-
activated receptor (PPAR) alpha activation increases adiponectin receptors
and reduces obesity-related inflammation in adipose tissue: comparison of
activation of PPARalpha, PPARgamma, and their combination. Diabetes
2004; 54: 3358–3370.
48 Ide T, Ontko JA. Increased secretion of very low density lipoprotein
triglyceride following inhibition of long chain fatty acid oxidation in isolated
rat liver. J Biol Chem 1981; 256: 10247–10255.
49 Brand-Miller JC, Holt SH, Pawlak DB, McMillan J. Glycemic index and
obesity. Am J Clin Nutr 2002; 76: 281S–285S.
50 van Can JG, Ijzerman TH, van Loon LJ, Brouns F, Blaak EE. Reduced
glycaemic and insulinaemic responses following isomaltulose ingestion:
implications for postprandial substrate use. Br J Nutr 2009; 102: 1408–1143.
51 Daitoku H, Yamagata K, Matsuzaki H, Hatta M, Fukamizu A. Regulation of
PGC-1 promoter activity by protein kinase B and the forkhead transcription
factor FKHR. Diabetes 2003; 52: 642–649.
52 Steineger HH, Sørensen HN, Tugwood JD, Skrede S, Spydevold O, Grautvik
KM. Dexamethasone and insulin demonstrate marked and opposite regula-
tion of the steady-state mRNA level of the peroxisomal proliferator-activated
receptor (PPAR) in hepatic cells. Hormonal modulation of fatty-acid-induced
transcription. Eur J Biochem 1994; 225: 967–974.